The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a more substantial decrease in body size and improve metabolic markers, parti